In return, OSE Immunotherapeutics gains the use of MAbSilico’s existing proprietary technology and algorithms. OSE Immunotherapeutics also gets early access to the deep tech startup’s Software as a Service, or SaaS — a type of service where the user pays for a license to software hosted by the provider, like many cloud storage websites. The SaaS — currently in development — will help users identify a therapeutic target and select a candidate antibody that can enter production.
Health data management company Seqster said this week that it has received a strategic investment of undisclosed size from Takeda Pharmaceuticals of Japan. Seqster, a software-as-a-service firm based in San Diego, plans to use the new funds to accelerate the adoption of its interoperability technology for enhancing clinical trials, patient engagement, and outcomes.